Pfizer Inc. announced the appointment of Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President, Research & Development, effective January 1, 2025. Dr. Boshoff, who previously served as Chief Oncology Officer, will oversee all R&D functions across therapeutic areas.
This leadership change follows a comprehensive internal and external selection process, with Dr. Boshoff succeeding Dr. Mikael Dolsten. Dr. Albert Bourla, Pfizer Chairman and CEO, stated that Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward with a more focused strategy, aiming to deliver impactful breakthrough medicines.
The appointment signals a continued strategic emphasis on oncology, with Roger Dansey serving as Interim Chief Oncology Officer and Johanna Bendell joining from Roche in 2025 as Chief Development Officer, Oncology. Dr. Boshoff's extensive experience, including delivering 24 approved innovative medicines and biosimilars, is expected to enhance Pfizer's pipeline productivity and focus on high-unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.